Ophthalmic Expertise EyeCRO offers specialized preclinical ophthalmic testing using a broad suite of disease models and proprietary MiDROPS formulation technology, making them a strong partner for late-stage ocular drug development and topical eye therapy programs.

Proprietary Delivery MiDROPS is a patented platform for delivering lipophilic drugs via eyedrops, enabling higher drug loading into the eye. This positions EyeCRO as a potential supplier for formulation development and optimization of challenging ocular compounds.

Strategic Collaborations Past and ongoing collaborations with major CROs and access to large mammalian models suggest EyeCRO can complement larger contract research networks, offering specialized ophthalmic preclinical services to augment scale when needed.

Engagement Momentum Active participation in industry events such as ARVO and a recent hire in pharmacology and bioanalytics indicate investment in scientific capability and business development, signaling readiness to engage with sponsors seeking advanced ocular models and analytics.

Growth Signals Revenue in the low to mid single digits with a lean team (11-50 employees) implies opportunities for wrap-around services, including regional business development, co-development of study designs, and scalable project management for expanding ophthalmic portfolios.